ARTICLE | Clinical News
IMC-C225: Expanded Phase II study
March 20, 2000 8:00 AM UTC
ImClone Systems Inc. (IMCL), New York, N.Y. Product: IMC-C225 Business: Cancer Therapeutic category: Antibody Target: EGFr Description: Monoclonal antibody against the epidermal growth factor recept...